Shots:

• The CHMP approval is based on data demonstrating analytical- preclinical- and clinical information- confirming biosimilar pegfilgrastim as a reference medicine in febrile neutropenia in terms of safety- efficacy and quality
• The biosimilar pegfilgrastim will be available in the 28 countries of EU post European Commission approval- which usually adopts CHMP positive opinion
• Pegfilgrastim is a long-acting form of filgrastim that stimulates the production of WBCs and stem cells and Sandoz- is seeking its approval as a reference medicine for Febrile Neutropenia in EU

Ref: Sandoz | Image: Elglobal